United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Center For Asset Management LLC

Center For Asset Management LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,686 shares of the biotechnology company’s stock after buying an additional 73 shares during the quarter. Center For Asset Management LLC’s holdings in United Therapeutics were worth $595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after acquiring an additional 50,291 shares during the last quarter. Franklin Resources Inc. increased its stake in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Burney Co. raised its holdings in shares of United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after buying an additional 12,705 shares during the last quarter. Bridgewater Associates LP lifted its stake in shares of United Therapeutics by 384.3% during the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock worth $22,130,000 after buying an additional 49,003 shares during the period. Finally, Glenmede Trust Co. NA grew its holdings in shares of United Therapeutics by 6.4% during the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock valued at $24,585,000 after buying an additional 4,145 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on UTHR. The Goldman Sachs Group lifted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $378.36.

United Therapeutics Trading Down 0.3 %

Shares of UTHR opened at $370.83 on Monday. The firm has a market cap of $16.56 billion, a P/E ratio of 16.29, a PEG ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock’s 50 day moving average is $365.19 and its two-hundred day moving average is $356.03.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the company earned $5.38 EPS. Equities research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $940,373.07. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 139,048 shares of company stock valued at $52,435,099 over the last 90 days. Corporate insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.